Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction

Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e745-e747. doi: 10.1016/j.clml.2021.05.014. Epub 2021 May 24.

Authors

Gerasimos Tsilimidos¹, Alice Horisberger², Camillo Ribi², Anne Cairoli³, Gregoire Stalder³

Affiliations

¹ Division and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne. Electronic address: [email protected].
² Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
³ Division and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne.

PMID: 34158264
DOI: 10.1016/j.clml.2021.05.014

No abstract available

Keywords: Desensitization; Hypersensitivity; Ibrutinib; Primary central nervous system lymphoma.

Publication types

Case Reports
Editorial

MeSH terms

Adenine / analogs & derivatives*
Adenine / pharmacology
Adenine / therapeutic use
Administration, Oral
Central Nervous System Neoplasms / drug therapy*
Female
Humans
Hypersensitivity, Immediate / drug therapy*
Middle Aged
Piperidines / pharmacology
Piperidines / therapeutic use*

Substances

Piperidines
ibrutinib
Adenine